BASi acquires Smithers Avanza’s tox services business unit

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pattonmania)
(Image: Getty/pattonmania)

Related tags: Basi, Bioanalytical, Toxicology, Smithers Avanza

Bioanalytical Systems acquires Smithers Avanza Toxicology Services business unit in response to a strong demand for its toxicology and drug disposition services.

Smithers Avanza is a Gaithersburg, MD-based contract research organization (CRO) specializing in general toxicology, vaccine safety, as well as developmental and reproductive toxicology (DART) studies.

Following the acquisition – funded in part by approximately $1.2m in cash – the company’s toxicology services business unit will operate under the name BASi Gaithersburg.

According to the company, Bioanalytical Systems (BASi) acquired substantially all of Smithers Avanza’s assets in connection with its in-vivo​ mammalian toxicology CRO services for pharmaceuticals – both small molecules and biologics – as well as vaccines, agro, and industrial chemicals.

BASi President and CEO Robert Leasure, Jr., said the company has seen strong demand for its toxicology and drug disposition services, and thus needed to add both space and talent.

“Operating as a single site toxicology business presented operational efficiency challenges that could be overcome with the added sites and in-house capabilities of BASi,”​ added Michael Hochschwender, president and CEO of The Smithers Group, in a statement.

Following its acquisition of Seventh Wave Laboratories in July 2018​, BASi announced a multi-phase investment at its GLP toxicology facility in Mt. Vernon, IN.

The expansion at the 52-acre campus near Evansville more than doubled its capacity for the development of protein-based therapeutics.

Related news

Show more

Related products

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more